All In MedTech

Device Trial Radar · NCT07349121

OPTION-EMEA Clinical Trial

Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation - Europe, Middle East and Africa [OPTION-EMEA]

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Jun 18, 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Jan 16, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one interventional case. The study will include patients that are clinically indicated for atrial fibrillation (AF) ablation using the FARAPULSE PFA System and for left atrial appendage closure (LAAC) treatment using a WATCHMAN FLX Pro or WATCHMAN FLX device as part of the patient's standard of care determined by their doctor's medical judgement.

Conditions

  • Atrial Fibrillation (AF)
  • Stroke Prevention in Patients With Atrial Fibrillation
  • Left Atrial Appendage Closure
  • Pulsed Field Ablation
  • Atrial Fibrillation Ablation Procedure
  • Concomitant Procedures

Interventions

  • Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional caseDevice

    left atrial appendage closure

  • Concomitant Pulsed Field Ablation and Left Atrial Appendage ClosureProcedure

    FARAPULSE PFA and WATCHMAN FLX Pro or WATCHMAN FLX in one interventional case.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety Endpoint (PSE): Device or Procedure Related Serious Adverse EventsTime frame: 30 days following the index procedure.
  2. Primary Efficacy Endpoint (PEE): Acute Treatment SuccessTime frame: Through 30 days

Locations

11 sites in 5 countries. Site status is shown where the registry gives one.

  • AZORG - Hospital

    Aalst, Belgium · Recruiting

  • UZ Brussel (AZ VUB)

    Brussels, Belgium · Recruiting

  • Klinicki bolnicki centar Zagreb

    Zagreb, Croatia · Recruiting

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.